Benjamin Graham Detailed Fundamental Analysis

Validea's Benjamin Graham 'Value Investor' model rated Intuitive Surgical (ISRG) at 71%, falling below the 80% threshold for 'some interest' for value investors. While ISRG passed operational metrics such as sales, debt, and long-term EPS growth, it failed the critical low P/E and Price/Book ratio tests, which are central to Graham's deep value methodology. This indicates that despite its fundamental strengths, ISRG's current valuation does not align with a strict deep value investment approach.

Analysis

Intuitive Surgical (ISRG) receives a mixed evaluation from Validea's Benjamin Graham-based value investing model, achieving a score of 71%, which is below the 80% threshold indicating active interest from a deep value perspective. The analysis reveals a clear dichotomy in the company's profile: while ISRG demonstrates strong operational health by passing criteria for sales, current ratio, long-term EPS growth, and low long-term debt relative to net current assets, it fails on key valuation metrics. Specifically, its Price-to-Earnings (P/E) and Price-to-Book (P/B) ratios are too high to meet the strict standards of Graham's deep value methodology. This outcome underscores the conflict between ISRG's classification as a 'large-cap growth stock' and the requirements of a traditional value screening, suggesting that while the company's fundamentals are sound, its market valuation does not align with a disciplined value investment strategy.

Key Decisions for Investors

• Strict value investors following a Graham-style approach should exercise caution, as ISRG's high P/E and P/B ratios disqualify it based on core valuation principles, despite its solid underlying fundamentals.
• Growth-oriented investors may view the report's findings on strong long-term EPS growth and a healthy balance sheet as a confirmation of fundamental quality, justifying a deeper analysis into whether its growth trajectory warrants the premium valuation.
• Investors should use this analysis to weigh the trade-off between ISRG's proven operational strength and its expensive valuation, a central dilemma for a stock exhibiting both strong growth and high-multiple characteristics.